Therapeutic Area | MeSH |
---|---|
neoplasms | D009369 |
respiratory tract diseases | D012140 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
KRAZATI | Bristol Myers Squibb | N-216340 RX | 2022-12-12 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
krazati | New Drug Application | 2024-07-11 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
non-small-cell lung carcinoma | — | D002289 | — |
Expiration | Code | ||
---|---|---|---|
ADAGRASIB, KRAZATI, MIRATI THERAPS | |||
2029-12-12 | ODE-352 | ||
2027-12-12 | NCE |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Adagrasib, Krazati, Mirati Theraps | |||
10689377 | 2037-05-17 | DS, DP | U-3490 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Non-small-cell lung carcinoma | D002289 | — | — | 5 | 7 | 4 | — | 1 | 14 |
Lung neoplasms | D008175 | — | C34.90 | 4 | 5 | 3 | — | 1 | 11 |
Colorectal neoplasms | D015179 | — | — | 4 | 2 | 1 | — | — | 5 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 13 | 7 | — | — | 1 | 16 |
Neoplasm metastasis | D009362 | EFO_0009708 | — | 5 | 5 | — | — | — | 7 |
Brain neoplasms | D001932 | EFO_0003833 | C71 | — | 2 | — | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Colonic neoplasms | D003110 | — | C18 | 2 | — | — | — | — | 2 |
Carcinoma | D002277 | — | C80.0 | 1 | — | — | — | 1 | 2 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | — | — | — | 1 |
Gastrointestinal neoplasms | D005770 | — | C26.9 | 1 | — | — | — | — | 1 |
Intestinal neoplasms | D007414 | — | C26.0 | 1 | — | — | — | — | 1 |
Renal cell carcinoma | D002292 | EFO_0000376 | — | 1 | — | — | — | — | 1 |
Pancreatic ductal carcinoma | D021441 | — | — | 1 | — | — | — | — | 1 |
Kidney neoplasms | D007680 | EFO_0003865 | C64 | 1 | — | — | — | — | 1 |
Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Small cell lung carcinoma | D055752 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Adagrasib |
INN | adagrasib |
Description | Adagrasib, sold under the brand name Krazati, is an anticancer medication used to treat non-small cell lung cancer. Adagrasib is an inhibitor of the RAS GTPase family. It is taken by mouth. It is being developed by Mirati Therapeutics.
|
Classification | Small molecule |
Drug class | Kirsten rat sarcoma (KRAS) inhibitors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N |
PDB | — |
CAS-ID | 2326521-71-3 |
RxCUI | — |
ChEMBL ID | CHEMBL4594350 |
ChEBI ID | — |
PubChem CID | 138611145 |
DrugBank | DB15568 |
UNII ID | 8EOO6HQF8Y (ChemIDplus, GSRS) |